Close menu




March 23rd, 2021 | 14:00 CET

BioNTech, Marble Financial, Disney: Innovations that pay off

  • Investments
Photo credits: pixabay.com

The stock market is where the future is traded. Groundbreaking innovations can completely change this future and provide investors with high returns from the very beginning. Examples include all investors who took an early stake in shares of Amazon or Alphabet. There are also currently a whole series of shares that stand for innovation. We present three stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: US09075V1026 , CA5660551097 , US2546871060

Table of contents:


    Everything is possible with BioNTech

    One of the stocks of 2020 is that of Mainz-based biotech Company BioNTech. The Company was an early bet on mRNA technology and originally planned to use it in the fight against cancer. When news of the novel virus from Wuhan spread worldwide in the first weeks of 2020, the Mainz-based Company reacted quickly. It developed the idea of an mRNA vaccine against Covid-19, which, in simplified terms, uses parts of the virus' genetic information to trigger an immune response in the vaccinees' bodies. Since the genetic material is very sensitive, it is impossible, according to current knowledge, for it to leave the muscle into which the vaccine has been injected.

    Although BioNTech's innovation has so far had the disadvantage that the vaccine needs to be cooled more, the vaccine is said to have several advantages. It is also said to work well with variants of the coronavirus. If more extensive mutations occur, the method used is also said to bring time advantages in developing new vaccines. Although BioNTech's stock has not been rising steadily for some time, the Company remains promising. The need for vaccines will continue. In addition, after this success, BioNTech will have an easy time developing other, innovative mRNA-based products. A kind of vaccination against cancer would be a milestone for the Company, which would also dwarf everything around BioNTech so far on the stock market. The stock is always attractive, regardless of its short-term situation.

    Marble Financial: This fintech lifts data treasures

    One stock that also has excellent innovation potential is Marble Financial. In recent weeks, market watchers in North America have been discussing a new fintech boom in the wake of the Corona Crisis. Marble Financial relies on artificial intelligence and big data analytics to help over-indebted people. For example, its ScoreUp service ensures that people with high credit scores get tangible tips on how to improve their situation. Other offerings from Marble include support for customers in personal insolvency, which results in these people being able to participate in economic life again sooner.

    Although one might wonder how Marble plans to make money from over-indebted customers given its business model, the Company is on a rapid growth trajectory. It plans to increase its revenue many times over between the end of 2020 and 2023. The reason for this is the size of the market Marble Financial is addressing. There are more than 12 million over-indebted people in Canada alone. With Marble's support, which includes financial education programs, these people get back into the economic cycle and ultimately become paying customers. Along the way, Marble is gaining a vast trove of data that the Company knows how to leverage for innovative products. Marble has entered into cooperation agreements with marketing partners in recent months and is also in talks with credit card providers. If business with over-indebted people in Canada continues to go well, the Company can even imagine expanding into other regions. The neighboring country of the USA, for example, would be an obvious choice.

    Disney: Streaming boosts the share price

    Disney is currently also expanding into new regions with its streaming service Disney+. Although the giant corporation started with its offer far after Amazon or Netflix, Disney+ is winning customer after customer. The reason for this is the extensive rights portfolio of the world's best-known media Group. From Mickey Mouse to the latest comic book adaptations - Disney has everything on offer and is also big enough to play to its strengths confidently. The Company, which was still rather analog a few years ago, has taken advantage of digitization and - like a startup - simply launched a new business. Disney+ is well received by users.

    The share price is also jubilant: it went up by more than 80% last year. Since Disney doesn't even cover all markets with Disney+ yet and the service is still relatively new, there is further growth potential. Nevertheless, investors should keep in mind that the stock, like BioNTech, has already done well. While anything can happen with BioNTech over the long term, the hype around video streaming will eventually die down. Meanwhile, an innovative stock that is still in its infancy could be Marble Financial. The large number of over-indebted people in North America and its data-driven approach could make the fintech an insider's tip. The market capitalization is currently around EUR 12 million.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read